Related Experiment Video
Updated: May 8, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
Clindamycin-induced acute kidney injury: large biopsy case series
Honglang Xie1, Huiping Chen, Yangling Hu
1Research Institute of Nephrology, Jinling Hospital, Nanjing University Clinical School of Medicine, Nanjing, PR China.
Background:
While clindamycin-induced acute kidney injury (AKI) is uncommon, it has occurred more frequently in recent years.
Summary:
We investigated 24 patients diagnosed with clindamycin-induced AKI retrospectively. The dosage of clindamycin was 1.0-1.5 g/day. Fifteen patients had episodes of gross hematuria, but fever, skin rash and eosinophilia were rare. Urine analysis revealed mild proteinuria and severe tubular dysfunction. Twenty-three patients were diagnosed with AKI stage 3 upon admission. The clindamycin lymphocyte transformation assay was positive for 63.2% of the patients. Acute interstitial nephritis (AIN) and acute tubular necrosis (ATN) were proven by renal biopsy, and renal insufficiency appeared to result from tubular toxicity and drug crystals. In the majority (87.5%) of the patients, AKI was severe and required renal replacement therapy, but all of their renal function recovered significantly 2 months after discharge. Clindamycin-induced AKI is largely reversible and has episodes of gross hematuria. Renal biopsies confirmed AIN or ATN in these patients.
Insights
Clindamycin-induced acute kidney injury (AKI) is uncommon but increasing. This study found AKI often presents with gross hematuria and severe tubular dysfunction, but is largely reversible with treatment.
Area of Science:
- Nephrology
- Pharmacology
- Toxicology
Background:
- Clindamycin-induced acute kidney injury (AKI) is an uncommon but increasingly reported adverse drug reaction.
- Recent years have seen a rise in documented cases of clindamycin-associated kidney damage.
Purpose of the Study:
- To investigate the clinical characteristics, renal biopsy findings, and outcomes of patients with clindamycin-induced AKI.
- To understand the mechanisms and reversibility of kidney injury associated with clindamycin use.
Main Methods:
- Retrospective analysis of 24 patients diagnosed with clindamycin-induced AKI.
- Review of patient data including clindamycin dosage, clinical presentation, urine analysis, and renal biopsy results.
- Assessment of renal function recovery post-treatment and use of clindamycin lymphocyte transformation assay.
Main Results:
- The majority of patients (23/24) presented with AKI stage 3, often with gross hematuria (15 patients).
- Renal biopsies confirmed acute interstitial nephritis (AIN) and/or acute tubular necrosis (ATN), linked to tubular toxicity and drug crystals.
- Severe AKI requiring renal replacement therapy occurred in 87.5% of patients, with significant renal function recovery observed within 2 months post-discharge.
Conclusions:
- Clindamycin-induced AKI is characterized by severe tubular dysfunction and often gross hematuria.
- Histopathological findings include AIN and ATN, indicating tubular toxicity as a primary mechanism.
- Despite severity, clindamycin-induced AKI is largely reversible, highlighting the importance of early diagnosis and management.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury III: Clinical Manifestations
Acute Pyelonephritis II: Diagnostic Studies and Management
Nephrotic Syndrome I : Introduction
